New article in BioStock: CombiGene comments on recent progress
CombiGene has recently raised more than SEK 25 million through two successful warrants, which were excercised at 98.4 percent. At the same time, CombiGene’s two gene therapy projects continue to be developed according to plan and the company’s studies within the epilepsy project have attracted international attention through an article in Frontiers in Molecular Neuroscience by Associate Professor David Woldbye, one of CombiGene’s scientific founders.
Read the full article here: https://www.biostock.se/en/combigene-comments-on-their-latest-progress/
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.